Last updated: July 28, 2026
ecutive summary: The antitrust indirect purchaser case “Picone v. Shire U.S. Inc.” (D. Mass., No. 1:16-cv-12396-ADB) is a putative class action alleging anticompetitive conduct by Shire that impaired competition in a branded pharmaceutical market. The litigation centers on whether the alleged conduct (and any related agreements or market practices) can be attributed to Shire and whether indirect purchasers can plausibly establish antitrust injury and class-wide impact under U.S. antitrust law. The case posture, rulings, and settlement or dismissal outcomes are not provided in the request, and without the specific docket events and opinion text it is not possible to produce a complete, accurate litigation summary and analysis.
What happened in Picone v. Shire U.S. Inc. 1:16-cv-12396-ADB (indirect purchaser antitrust class action)?
Answer: The case is filed as an indirect purchaser class action in the District of Massachusetts alleging anticompetitive conduct by Shire that harmed purchasers of a pharmaceutical product(s). A complete litigation summary requires specific docket milestones (motions to dismiss, class certification, summary judgment, trial, settlement, or appeal) and the substantive holdings contained in the court’s orders.
What claims are typically pled in indirect purchaser pharmaceutical antitrust class actions?
Indirect purchaser pharmaceutical antitrust theories usually include:
- Alleged monopolization or restraint of trade under the Sherman Act.
- Alleged unlawful agreements under the Sherman Act Section 1.
- State-law antitrust or consumer protection statutes depending on the named class.
- Overcharge and antitrust injury through pass-through and pricing impact models.
What must plaintiffs prove at class stage in U.S. indirect purchaser cases?
Class certification and merits often hinge on:
- Existence of a conspiracy or anticompetitive conduct connected to the defendant.
- Causation and antitrust impact using a model that supports generalized proof.
- Reliability of damages/overcharge attribution for indirect purchasers.
What motions were filed and what rulings came out in Picone v. Shire (ADB) 1:16-cv-12396-ADB?
Answer: A litigation summary must cite the court’s orders (date, document number, and holding). Those details are not present in the request.
Motion-to-dismiss questions
Key issues that courts address in pharmaceutical antitrust pleadings:
- Sufficient factual basis for a conspiracy or monopolistic conduct.
- Market definition and plausible market power allegations.
- Legal sufficiency of antitrust injury and proximate cause for indirect purchasers.
- Limits under Illinois Brick and related indirect purchaser doctrines (including exceptions and pleading of pass-through).
Discovery and class certification questions
If the case proceeded:
- Whether evidence supports class-wide impact rather than individualized proof.
- Whether plaintiff’s economic model is consistent with alleged wrongdoing.
- Whether predominance under Rule 23(b)(3) is met.
How strong was Picone’s antitrust case against Shire U.S. Inc. under antitrust pleading standards?
Answer: Strength depends on the court’s handling of:
- Market power and market definition.
- Alleged conduct characterization (unilateral vs concerted).
- Causation and pass-through logic for indirect purchasers.
- Whether alleged conduct plausibly produced sustained supracompetitive prices.
A credible “strength” assessment requires the actual court reasoning in the dismissal/class certification opinions.
What is the settlement or dismissal status of Picone v. Shire U.S. Inc. 1:16-cv-12396-ADB?
Answer: Settlement/dismissal outcome is not provided. A complete status report requires:
- Final disposition (dismissed, stayed, settled, or ongoing).
- Settlement agreement terms (if any).
- Whether any appeals or related MDL proceedings exist.
How does Illinois Brick and indirect purchaser standing apply in Picone v. Shire?
Answer: Indirect purchaser standing is generally the core statutory and doctrinal gatekeeping issue. Courts evaluate:
- Whether plaintiffs fit within indirect purchaser class definition.
- Whether the alleged overcharge passed through the distribution chain.
- Whether Illinois Brick bars direct purchaser recovery while preserving indirect purchaser claims.
Specific analysis of how the court ruled in this case requires the opinion or order text.
What generic or branded drug market issues are implicated by Shire’s alleged conduct in Picone?
Answer: The request does not specify which Shire product(s) are at issue. A market-focused analysis requires identifying:
- The active ingredient(s) and formulation(s) implicated.
- Brand vs generic/biosimilar landscape during the class period.
- Entry dates, exclusivity periods, and any parallel IP litigation impacting competition.
Without product identification and class period information, market analysis cannot be completed accurately.
Which patents or exclusivities matter to antitrust allegations involving Shire in Picone?
Answer: Antitrust cases in branded drug markets often overlap with:
- Exclusivity-driven barriers to entry (FDA exclusivity, patent thickets).
- Whether alleged conduct is tied to settlement practices, reverse payments, or exclusionary agreements.
- Whether litigation settlement triggers Noerr-Pennington or antitrust immunity doctrines (depending on conduct and timing).
The request does not provide the conduct theory or the product-specific IP context, so a patent/exclusivity linkage analysis cannot be generated reliably.
How would a court evaluate antitrust impact and damages models in Picone’s indirect purchaser class?
Answer: Courts typically scrutinize:
- Whether the damages model matches the theory of liability.
- Whether the model captures all relevant competitive constraints.
- Whether pass-through assumptions hold across the class.
- Whether the class period and “but-for” world are defined consistently with conduct allegations.
A case-specific evaluation requires reference to the pleadings and any expert filings/opinion excerpts.
Key Takeaways
- Picone v. Shire U.S. Inc. (D. Mass., No. 1:16-cv-12396-ADB) is a putative indirect purchaser antitrust class action, but the request does not include the docket and ruling record needed for an accurate litigation summary and analysis.
- A litigation-grade analysis depends on identifying the exact product(s), class period, asserted antitrust theories, and the court’s concrete rulings on motion practice and class certification.
- Without the specific opinions/orders and procedural outcomes, any summary would be incomplete.
FAQs
- What is the procedural posture of 1:16-cv-12396-ADB and what was the last docket event?
- What specific Shire product(s) were implicated and what class period did plaintiffs allege?
- What antitrust theories (Sherman Act Section 1 vs Section 2) were pleaded in Picone?
- Did the court certify an indirect purchaser class or dismiss key claims at the pleading stage?
- Was the case stayed, consolidated, or coordinated with any related pharmaceutical antitrust MDL?
References
- No sources were cited because the request did not include docket/ruling details or opinion text, and no verifiable citations are provided.
